Table 3.
Vaccine schedule | Day |
Geometric mean concentration day 28–0 | ||
---|---|---|---|---|
0 | 14 | 28 | ||
Geometric mean (GM) | ||||
rAd26/rAd5 | 0.726 | 1.587 | 1.834 | 9.77 (5.26–18.14) |
rAd26/ChAdOx1 | 0.881 | 1.972 | 2.131 | 8.98 (2.87–28.09) |
rAd26/BBIBP-CorV | 0.782 | 0.870 | 1.041 | 1.64 (0.14–4.14) |
GMC ratioa | ||||
rAd26/rAd5 | 1.00 | 1.00 | 1.00 | |
rAd26/ChAdOx1 | 2.30 (0.79–6.68) | 2.34 (1.14–4.81) | 2.12 (0.99–4.51) | |
rAd26/BBIBP-CorV | 1.26 (0.60–2.62) | 0.24 (0.11–0.52) | 0.21 (0.09–0.47) | |
No. of participants | 30 | 30 | 28 | |
25b | 23c | 27 | ||
27 | 26 | 25 |
GMC ratio was calculated as the antilogarithm of the difference between the mean of the log10 transformed SARS-CoV-2 anti-spike IgG in the heterologous groups and that in rAd26/rAd5 (as reference category).
Blood samples could not be collected for 2 participants.
Blood samples could not be collected for 4 participants.